Integrating systemic therapy in the earlier stages of liver cancer.

Integrating systemic therapy earlier in liver cancer shows promising but uncertain benefits, with advances in hepatocellular carcinoma and biliary tract cancers.

• Why it matters: Early-stage treatment strategies are crucial to improve long-term outcomes, yet designing trials that combine local and systemic therapies remains challenging, creating a gap in evidence.
• What they did: The review analyzes data from 16 studies on intra-arterial and systemic treatments in hepatocellular carcinoma and discusses recent developments in adjuvant and neoadjuvant therapies for both HCC and biliary tract cancers.
• The result: While early results are promising, uncertainties persist about whether these combined approaches will become standard care, highlighting the need for further research to confirm their efficacy.